|1.||Juul, Sandra E: 7 articles (10/2014 - 01/2007)|
|2.||McPherson, Ronald J: 6 articles (12/2009 - 01/2007)|
|3.||Mogensen, Jesper: 5 articles (09/2008 - 02/2004)|
|4.||Malá, Hana: 5 articles (09/2008 - 02/2004)|
|5.||Musto, Pellegrino: 4 articles (08/2010 - 07/2003)|
|6.||Falcone, Antonietta: 3 articles (08/2010 - 07/2003)|
|7.||Sanpaolo, Grazia: 3 articles (08/2010 - 07/2003)|
|8.||Daneryd, Peter: 3 articles (01/2008 - 10/2004)|
|9.||Lundholm, Kent: 3 articles (01/2008 - 10/2004)|
|10.||Körner, Ulla: 3 articles (01/2008 - 10/2004)|
04/01/1992 - "Human recombinant erythropoietin constitutes a remarkable improvement in the treatment of uraemic anemia. "
10/08/1988 - "Human recombinant erythropoietin (r-huEPO) is very effective in the treatment of anemia of hemodialyzed patients. "
06/01/1999 - "Our case report shows that recombinant erythropoietin gives good results in treatment of anemia: correction of anemia, improvement of general status and there is no need for frequent transfusions and thus there are less complications."
09/01/1995 - "Such strategies include collection and banking of autologous placental blood, administration of recombinant erythropoietin, innovations in blood banking practices, and improved definitions of the markers of anemia with more rigorous transfusion guidelines. "
03/01/2003 - "Human recombinant erythropoietin is the main treatment for anemia in renal patients. "
|2.||Chronic Kidney Failure (Chronic Renal Failure)
01/01/2003 - "Recombinant erythropoietin (Epo) therapy is well established as an effective treatment for the anaemia of end-stage renal disease. "
01/01/1989 - "Administration of recombinant erythropoietin (r-HuEPO) is an effective treatment for the anaemia of chronic renal failure, but in some patients it has been accompanied by elevated blood pressure. "
01/01/1994 - "Study of the effect of recombinant erythropoietin on renal anaemia in predialysis patients with chronic renal failure."
07/01/2008 - "For poorly understood reasons, patients with end-stage renal disease (ESRD) differ substantially in their response to treatment with recombinant erythropoietin (EPO). "
06/01/2005 - "Immunologically mediated PRCA is by far the commonest cause in adults, particularly since 1998, when a marked increased incidence of PRCA was noted in chronic renal failure patients receiving subcutaneous (SC) recombinant erythropoietin (rEpo). "
09/15/2015 - "Cancer-associated anaemia may be treated with recombinant erythropoietin. "
01/01/2015 - "In contrast, no activation by human recombinant erythropoietin was observed in isolated tumor cells. "
04/01/2009 - "Recombinant erythropoietin-stimulating agents have been used to ameliorate the symptoms of anaemia in cancer patients. "
02/01/2008 - "The role of recombinant erythropoietin in childhood cancer."
01/01/2008 - "Recombinant erythropoietin (rhEPOalpha) corrects anaemia, improves physical functioning and quality of life in cancer patients. "
|4.||Myelodysplastic Syndromes (Myelodysplastic Syndrome)
02/01/2009 - "The efficacy of human recombinant erythropoietin (rEPO) in myelodysplastic syndromes (MDS) has generally been best in untransfused patients with 'refractory anaemia' according to the World Health Organization (WHO). "
06/01/1993 - "We studied the efficacy of high doses (100,000 IU intravenously (IV)/twice a week) of human recombinant erythropoietin (rHuEpo) in patients with transfusion dependent myelodysplastic syndromes (MDS). "
12/01/2003 - "Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes."
07/01/2003 - "Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes."
12/01/1994 - "To study the usefulness of different published epidemiological and analytic parameters to decide the treatment with human recombinant erythropoietin (rHuEPO) of anaemic patients with myelodysplastic syndromes (MDS). "
05/02/2007 - "Correction of anemia in CHF patients using recombinant erythropoietin is feasible; small studies suggest that anemic congestive heart failure patients may have improved morbidity with this therapy. "
01/01/2001 - "Randomized, controlled trials have shown that normalization of haemoglobin (Hb) with recombinant erythropoietin (rh-Epo) is of no cardiovascular benefit in haemodialysis patients with symptomatic heart failure, ischaemic heart disease, or severe left ventricular dilatation, although suggestive evidence exists for benefits at earlier stages of cardiac disease. "
01/01/2005 - "By targeting hemoglobin levels in anemic patients with CKD, through the use of recombinant erythropoietin (epoetin) therapy, it has been hoped that anemia, CKD, and heart failure outcomes can be improved. "
08/12/2008 - "Indeed, several small-sized studies have shown the beneficial effects of empirically treating anemia in heart failure patients with recombinant erythropoietin and intravenous iron. "
|3.||Epoetin Alfa (Epogen)
|4.||Granulocyte Colony-Stimulating Factor (G-CSF)
|6.||Tissue Plasminogen Activator (Alteplase)
|7.||Cholecalciferol (Vitamin D3)
|10.||darbepoetin alfa (Aranesp)
|1.||Renal Dialysis (Hemodialysis)
|2.||Blood Transfusion (Blood Transfusions)
|3.||Drug Therapy (Chemotherapy)